CN101970659A - 基于hiv特异性抗体的hiv预防疫苗 - Google Patents

基于hiv特异性抗体的hiv预防疫苗 Download PDF

Info

Publication number
CN101970659A
CN101970659A CN2008801156626A CN200880115662A CN101970659A CN 101970659 A CN101970659 A CN 101970659A CN 2008801156626 A CN2008801156626 A CN 2008801156626A CN 200880115662 A CN200880115662 A CN 200880115662A CN 101970659 A CN101970659 A CN 101970659A
Authority
CN
China
Prior art keywords
hiv
recombinant
peptide
peptides
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801156626A
Other languages
English (en)
Chinese (zh)
Inventor
依伦娜·于·菲利诺娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technologie Integrale Ltd
Original Assignee
Technologie Integrale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Ltd filed Critical Technologie Integrale Ltd
Publication of CN101970659A publication Critical patent/CN101970659A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801156626A 2007-10-09 2008-10-09 基于hiv特异性抗体的hiv预防疫苗 Pending CN101970659A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97853607P 2007-10-09 2007-10-09
US60/978,536 2007-10-09
PCT/EP2008/008544 WO2009046984A1 (en) 2007-10-09 2008-10-09 Hiv preventive vaccine based on hiv specific antibodies

Publications (1)

Publication Number Publication Date
CN101970659A true CN101970659A (zh) 2011-02-09

Family

ID=40342551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801156626A Pending CN101970659A (zh) 2007-10-09 2008-10-09 基于hiv特异性抗体的hiv预防疫苗

Country Status (12)

Country Link
US (1) US20100215695A1 (cg-RX-API-DMAC7.html)
EP (1) EP2205736B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010540674A (cg-RX-API-DMAC7.html)
KR (1) KR20100098597A (cg-RX-API-DMAC7.html)
CN (1) CN101970659A (cg-RX-API-DMAC7.html)
AU (1) AU2008309940B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818354A2 (cg-RX-API-DMAC7.html)
CA (1) CA2701948A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010003762A (cg-RX-API-DMAC7.html)
RU (1) RU2505604C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009046984A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002445B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102190726A (zh) * 2011-03-30 2011-09-21 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
CN102212133A (zh) * 2011-03-30 2011-10-12 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422618A1 (en) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
JP2014527085A (ja) * 2011-09-17 2014-10-09 スーチョウ ナアオ ニュー マテリアル サイエンシーズ カンパニー リミテッド ペプチドにおける３個以上のアミノ酸残基の任意に設計されたエピトープを認識する抗体およびその生成方法
US10660951B2 (en) 2012-09-17 2020-05-26 Zhiwei Allen Wu Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
RU2600031C2 (ru) * 2014-11-11 2016-10-20 Публичное акционерное общество "Фармсинтез" Лекарственная форма специфического иммунобиологического лекарственного средства для лечения и профилактики вич инфекции и способ ее получения
US11067583B2 (en) 2016-05-25 2021-07-20 University Of Maryland, Baltimore Methods of making active antibodies from biological fluids
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
US20200172601A1 (en) 2017-06-22 2020-06-04 University Of Maryland, Baltimore Broadly neutralizing antibodies against hiv
IT202100004172A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Nuova composizione
IT202100004160A1 (it) * 2021-02-23 2022-08-23 Univ Degli Studi Milano Cellula ospite di leishmania

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2237065C2 (ru) * 2002-10-03 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BELSHE ET AL. ,: "Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection", 《THE JOURNAL OF INFECTIOUS DISEASES》 *
CHOUDHRY ET AL.: "Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies", 《VIROLOGY》 *
HANSEN ET AL. ,: "An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1env gene recombinant vaccinia virus", 《ARCHIVES OF VIROLOGY》 *
SANDERS ET AL.,: "The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120", 《JOURNAL OF VIROLOGY》 *
V BASE: "V Base PCR primers for rearranged V genes", 《V BASE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102190726A (zh) * 2011-03-30 2011-09-21 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用
CN102212133A (zh) * 2011-03-30 2011-10-12 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102212133B (zh) * 2011-03-30 2013-01-16 中国医学科学院病原生物学研究所 人源HIV抗体的Fab片段及其编码基因与应用
CN102190726B (zh) * 2011-03-30 2013-03-27 中国医学科学院病原生物学研究所 一种人源HIV抗体的Fab片段及其编码基因与应用

Also Published As

Publication number Publication date
AU2008309940A1 (en) 2009-04-16
EP2205736B1 (en) 2014-04-02
KR20100098597A (ko) 2010-09-08
JP2010540674A (ja) 2010-12-24
AU2008309940B2 (en) 2013-11-14
WO2009046984A1 (en) 2009-04-16
RU2010116849A (ru) 2011-11-20
BRPI0818354A2 (pt) 2017-05-16
ZA201002445B (en) 2011-03-30
MX2010003762A (es) 2010-09-10
CA2701948A1 (en) 2009-04-16
RU2505604C2 (ru) 2014-01-27
EP2205736A1 (en) 2010-07-14
US20100215695A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
CN101970659A (zh) 基于hiv特异性抗体的hiv预防疫苗
US10946090B2 (en) Consensus/ancestral immunogens
ES2251734T3 (es) Genes sinteticos de hiv.
EP0689551B1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
JP5932647B2 (ja) エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用
KR20020013537A (ko) 면역 반응을 유발하는 항원을 동정하기 위한 조성과 방법
US8148130B2 (en) T4 bacteriophage bound to a substrate
JP2007244394A (ja) 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
Kameoka et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular α antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop
US8754015B2 (en) Modified phage for displaying post-translationally modified proteins and uses thereof
Urban et al. Retroviral display in gene therapy, protein engineering, and vaccine development
HK1151554A (en) Hiv preventive vaccine based on hiv specific antibodies
KR101756202B1 (ko) 신규한 ｇｐ41 항원
WO2010051215A1 (en) Methods for making hiv vaccines and related compositions
KR101067231B1 (ko) Ｈｉｖ-ｇａｇ 코돈-최적화된 ｄｎａ 백신
CN101588813A (zh) 诱导人类免疫缺陷病毒的中和抗体的方法
WO2025189436A1 (zh) 针对猫fipv的多表位抗原构建环状rna疫苗的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1151554

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20151028

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1151554

Country of ref document: HK